The SeNostic Health GmbH is a diagnostics start-up company founded in 2017 and located at Hannover's Medical Park, Germany. SeNostic develops its proprietary SeedCycler® technology platform for the precise and accurate early differential diagnosis of neurodegenerative disorders, including Alzheimer’s disease, dementia with Lewy bodies or Parkinson’s disease.
The development of the underlying SeedCycler® technology platform is funded by the European Regional Development Fund under the Innovation Promotion Program of Lower Saxony.
The analysis process of SeNostic provides a unique way to amplify disease-specific protein aggregates (Seed-biomarkers) present in tissues and body fluids. These are characteristic for pathological disease processes, and increase over disease progression. The potential for highly accurate in vitro diagnostics, which especially avoids false-positive results, has a world-wide market potential for today’s clinical diagnostics, for future preclinical diagnostics and for the stratification and follow-up of pharmaceutical clinical trials.
SeNostic also produces high-quality recombinant proteins that are involved in neurodegenerative disorders. These can be purchased for research use via SeNositc's web-site.